Use: Labeled indications
- INDICATIONS AND USAGE Cetrotide ® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Full indications and usage US FDA label
INDICATIONS AND USAGE Cetrotide ® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Contraindications
CONTRAINDICATIONS Cetrotide ® (cetrorelix acetate for injection) is contraindicated under the following conditions: Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. Known hypersensitivity to GnRH or any other GnRH analogs. Known or suspected pregnancy, and lactation (see PRECAUTIONS). Severe renal impairment
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3. The dose of gonadotropins should be adjusted according to individual response. Cetrotide ® (cetrorelix acetate for injection) 0.25 mg may be administered subcutaneously once daily during the early- to mid-follicular phase.
Cetrotide ® 0.25 mg is administered on either stimulation day 5 (morning or evening) or day 6 (morning) and continued daily until the day of hCG administration. When assessment by ultrasound shows a sufficient number of follicles of adequate size, hCG is administered to induce ovulation and final maturation of the oocytes.
No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS). Administration Cetrotide ® 0.25 mg can be administered by the patient herself after appropriate instructions by her doctor. Directions for using Cetrotide ® 0.25 mg with the enclosed needles and pre-filled syringe: Wash hands thoroughly with soap and water.
Flip off the plastic cover of the vial and wipe the aluminum ring and the rubber stopper with an alcohol swab. Twist the injection needle with the yellow mark (20 gauge) on the pre-filled syringe. Push the needle through the center of the rubber stopper of the vial and slowly inject the solvent into the vial. Leaving the syringe in the vial, gently swirl the vial until the solution is clear and without residues.
Avoid forming bubbles. Draw the total contents of the vial into the syringe. If necessary, invert the vial and pull back the needle as far as needed to withdraw the entire contents of the vial. Replace the needle with the yellow mark by the injection needle with the grey mark (27 gauge). Invert the syringe and push the plunger until all air bubbles have been expelled.
Choose an injection site in the lower abdominal area, preferably around, but staying at least one inch away from the navel. Choose a different injection site each day to minimize local irritation. Use a second alcohol swab to clean the skin at the injection site and allow alcohol to dry. Gently pinch up the skin surrounding the site of injection.
Inject the prescribed dose as directed by your doctor, nurse or pharmacist. Use the syringe and needles only once. Dispose of the syringe and needles properly after use. If available, use a medical waste container for disposal.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Cetrotide ® is not intended to be used in subjects aged 65 and over.
Dosage forms
Philippines
- Lyophilized powder for injection: 250 mcg
- Lyophilized powder for solution for injection: 250 mcg
Registered products in the Philippines
10 products registered with the Food and Drug Administration (FDA) Philippines list Cetrorelix as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products10
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AsporelixCetrorelix (as Acetate) | 250mcg Lyophilized Powder For Injection (SC)2 mL-capacity USP Type I Clear Colourless Tubular 1 Clear Glass Vial with 1 mL Ampoule of Sterile Water for Injection (as diluent) in a PVC Tray [Box of 1's ] | Rx | Bharat Serums and Vaccines LimitedIndia | Sandoval Distributors, Inc.Importer: BSV Bioscience Phils. Inc. | DR-XY48498 | Dec 16, 2027 | |
CetlixCetrorelix (as acetate) | 250 mcg Lyophilized Powder for Injection (S.C.)2 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and aluminum tear off seal (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc. | DRP-13813 | Apr 26, 2028 | |
CetrocordCetrorelix (as acetate) | 250 mcg Lyophilized Powder for Solution for Injection (S.C.)2-mL capacity USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (box of 1 vial) | Rx | Intas Pharmaceuticals LimitedIndia | Importer: Accord Healthcare Limited-Philippine Branch Office | DRP-12102 | Jun 13, 2027 | |
CetrolixCetrorelix (as acetate) | 250 mcg Lyophilized Powder for Injection (SC)2 mL-capacity USP Type I clear and colorless glass vial with 13 mm grey butyl rubber stopper and 13 mm yellow aluminum flip-off seal and 1 mL USP Type I clear and colorless glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | SRS Life Sciences Inc.Trader: SRS Pharmaceuticals Pvt. Ltd. | DR-XY47027 | Aug 28, 2030 | |
CetrostalCetrorelix (as acetate) | 250 mcg/500mcL Solution for Injection (SC)1 mL-capacity pre-filled syringe x 500 mcL in blister pack (Box of 1's) | Rx | Memphis Vision Care Pvt. Ltd.India | Ambica International Corporation.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd | DRP-15009 | Mar 11, 2029 | |
CetrothixCetrorelix (as acetate) | 250 mcg Lyophilized Powder for Injection (S.C.)2 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and aluminum tear off seal (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Medethix, Inc. | DRP-13812 | Apr 26, 2028 | |
CetrotideCetrorelix Acetate | 250 mcg Lyophilized Powder for Injection (SC)Blister Pack containing 1 vial Powder, 1 pre-filled syringe of diluents, 1 x 20 G needle, 27 G needle, 2 alcohol swabs (Box of 7's) | Rx | Baxter Oncology GmbHGermany | Merck, Inc. | DR-XY29116 | May 16, 2027 | |
CetrotideCetrorelix (as acetate) | 250mcg Lyophilized Powder For Injection2 mL-capacity Type I Clear and colorless glass vial with grey bromo butyl rubber stopper and aluminum seal with blue flip- off cap+ 1 mL-net content of Sterile Water for Injection in pre-filled syringe 20 G needle + 27 G needle + 2 Alcohol swabs in a plastic tray (Box of 7's plastic trays) | Rx | Fareva Pau 2France | Merck, Inc.Trader: Merck Europe B.V. | DR-XY48790 | Jun 30, 2028 | |
LHixCetrorelix (as acetate) | 250 mcg Lyophilized Powder for Injection (S.C.)2 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and aluminum tear off seal (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | I.E Medica Inc.Importer: Medethix, Inc. | DRP-13811 | May 4, 2028 | |
(no brand name)Cetrorelix (as acetate) | 250 mcg Lyophilized Powder for Injection (S.C.)2 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and aluminum tear off seal (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Medethix, Inc. | DRP-13810 | Apr 26, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Cetrotide ® (cetrorelix acetate for injection) should be prescribed by physicians who are experienced in fertility treatment. Before starting treatment with Cetrotide ®, pregnancy must be excluded (see CONTRAINDICATIONS and PRECAUTIONS).
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions No formal drug interaction studies have been performed with Cetrotide ®.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The safety of Cetrotide ® (cetrorelix acetate for injection) in 949 patients undergoing controlled ovarian stimulation in clinical studies was evaluated. Women were between 19 and 40 years of age (mean: 32). 94.0% of them were Caucasian. Cetrotide ® was given in doses ranging from 0.1 mg to 5 mg as either a single or multiple dose.
Table 3 shows systemic adverse events, reported in clinical studies without regard to causality, from the beginning of Cetrotide ® treatment until confirmation of pregnancy by ultrasound at an incidence ≥ 1% in Cetrotide ® treated subjects undergoing COS. Table 3: Adverse Events in ≥1% (WHO preferred term) Cetrotide ® N=949 % (n) Ovarian Hyperstimulation Syndrome Intensity moderate or severe, or WHO Grade II or III, respectively 3.5 (33) Nausea 1.3 (12) Headache 1.1 (10) Local site reactions (e.g. redness, erythema, bruising, itching, swelling, and pruritus) were reported.
Usually, they were of a transient nature, mild intensity and short duration. During post-marketing surveillance, cases of mild to moderate Ovarian Hyperstimulation syndrome and cases of hypersensitivity reactions including anaphylactoid reactions have been reported. Two stillbirths were reported in Phase 3 studies of Cetrotide ®.
Congenital Anomalies Clinical follow-up studies of 316 newborns of women administered Cetrotide ® were reviewed. One infant of a set of twin neonates was found to have anencephaly at birth and died after four days. The other twin was normal. Developmental findings from ongoing baby follow-up included a child with a ventricular septal defect and another child with bilateral congenital glaucoma.
Four pregnancies that resulted in therapeutic abortion in Phase 2 and Phase 3 controlled ovarian stimulation studies had major anomalies (diaphragmatic hernia, trisomy 21, Klinefelter syndrome, polymalformation, and trisomy 18). In three of these four cases, intracytoplasmic sperm injection (ICSI) was the fertilization method employed; in the fourth case, in vitro fertilization (IVF) was the method employed.
The minor congenital anomalies reported include: supernumerary nipple, bilateral strabismus, imperforate hymen, congenital nevi, hemangiomata, and QT syndrome. The causal relationship between the reported anomalies and Cetrotide ® is unknown. Multiple factors, genetic and others (including, but not limited to ICSI, IVF, gonadotropins, and progesterone) make causal attribution difficult to study.
Adverse reaction frequency tables (US label) US FDA label
| (WHO preferred term) | Cetrotide® N=949 % (n) |
|---|---|
| Ovarian Hyperstimulation SyndromeIntensity moderate or severe, or WHO Grade II or III, respectively | 3.5 (33) |
| Nausea | 1.3 (12) |
| Headache | 1.1 (10) |
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy (see CONTRAINDICATIONS) Cetrotide ® is contraindicated in pregnant women. When administered to rats for the first seven days of pregnancy, cetrorelix acetate did not affect the development of the implanted conceptus at doses up to 38 μg/kg (approximately 1 times the recommended human therapeutic dose based on body surface area).
However, a dose of 139 μg/kg (approximately 4 times the human dose) resulted in a resorption rate and a postimplantation loss of 100%. When administered from day 6 to near term to pregnant rats and rabbits, very early resorptions and total implantation losses were seen in rats at doses from 4.6 μg/kg (0.2 times the human dose) and in rabbits at doses from 6.8 μg/kg (0.4 times the human dose).
In animals that maintained their pregnancy, there was no increase in the incidence of fetal abnormalities. The fetal resorption observed in animals is a logical consequence of the alteration in hormonal levels effected by the antigonadotrophic properties of Cetrotide ®, which could result in fetal loss in humans as well.
Therefore, this drug should not be used in pregnant women.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether Cetrotide ® is excreted in human milk. Because many drugs are excreted in human milk, and because the effects of Cetrotide ® on lactation and/or the breast-fed child have not been determined, Cetrotide ® should not be used by nursing mothers.
Pharmacokinetics
Excretion Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine.
In 24 hours, cetrorelix and small amounts of the (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples. 2-4% of the dose was eliminated in the urine as unchanged cetrorelix, while 5-10% was eliminated as cetrorelix and the four metabolites in bile.
Pharmacokinetics (US label) US FDA label
Pharmacokinetics The pharmacokinetic parameters of single and multiple doses of Cetrotide ® (cetrorelix acetate for injection) in adult healthy female subjects are summarized in Table 1. Table 1: Pharmacokinetic parameters of Cetrotide ® following 3 mg single or 0.25 mg single and multiple (daily for 14 days) subcutaneous (sc) administration.
Single dose 3 mg Single dose 0.25 mg Multiple dose 0.25 mg t max Time to reach observed maximum plasma concentration t 1/2 Elimination half-life C max Maximum plasma concentration; multiple dose C ss, max AUC Area under the curve; single dose AUC 0-inf, multiple dose AUCt CL Total plasma clearance Vz Volume of distribution Geometric mean (95% CI ln), No. of subjects 12 12 12 t max median (min-max) [h] 1.5 (0.5-2) 1.0 (0.5-1.5) 1.0 (0.5-2) t 1/2 [h] 62.8 (38.2-108) 5.0 (2.4-48.8) 20.6 (4.1-179.3) C max [ng/ml] 28.5 (22.5-36.2) 4.97 (4.17-5.92) 6.42 (5.18-7.96) AUC [ng∙h/ml] 536 (451-636) 31.4 (23.4-42.0) 44.5 (36.7-54.2) CL arithmetic mean, [ml/min∙kg] 1.28 Based on iv administration (n=6, separate study 0013) Vz [l/kg] 1.16 Absorption Cetrotide ® is rapidly absorbed following subcutaneous injection, maximal plasma concentrations being achieved approximately one to two hours after administration. The mean absolute bioavailability of Cetrotide ® following subcutaneous administration to healthy female subjects is 85%.
Distribution The volume of distribution of Cetrotide ® following a single intravenous dose of 3 mg is about 1 l/kg. In vitro protein binding to human plasma is 86%. Cetrotide ® concentrations in follicular fluid and plasma were similar on the day of oocyte pick-up in patients undergoing controlled ovarian stimulation. Following subcutaneous administration of Cetrotide ® 0.25 mg and 3 mg, plasma concentrations of cetrorelix were below or in the range of the lower limit of quantitation on the day of oocyte pick-up and embryo transfer.
Metabolism After subcutaneous administration of 10 mg Cetrotide ® to females and males, Cetrotide ® and small amounts of (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples over 24 hours. In in vitro studies, Cetrotide ® was stable against phase I- and phase II-metabolism. Cetrotide ® was transformed by peptidases, and the (1-4) peptide was the predominant metabolite.
Excretion Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine. In 24 hours, cetrorelix and small amounts of the (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples. 2-4% of the dose was eliminated in the urine as unchanged cetrorelix, while 5-10% was eliminated as cetrorelix and the four metabolites in bile.
Therefore, only 7-14% of the total dose was recovered as unchanged cetrorelix and metabolites in urine and bile up to 24 hours. The remaining portion of the dose may not have been recovered since bile and urine were not collected for a longer period of time. Special Populations Pharmacokinetic investigations have not been performed either in subjects with impaired renal or liver function, or in the elderly, or in children (see PRECAUTIONS).
Pharmacokinetic differences in different races have not been determined. There is no evidence of differences in pharmacokinetic parameters for Cetrotide ® between healthy subjects and patients undergoing controlled ovarian stimulation.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cetrotide · EMD Serono, Inc. [US FDA-approved label, version 18, September 22, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .